Background. Angiographic progression of coronary atherosclerosis is frequently observed in clinical practice and is used as an end point in clinical trials; however, its prognostic significance is unclear.
C oronary disease progression is frequently used instead of coronary events as the end point of clinical trials of antiatherosclerotic agents because sample size requirements and the duration of follow-up can be greatly reduced. However, the prognostic significance of coronary progression, particularly in asymptomatic patients who undergo repeat arteriography as part of a study, is unclear. Coronary events such as unstable angina1 and myocardial infarction2 are a consequence of coronary progression, but most progression occurs silently, without worsening symptoms or a clinical event. The validity of using progression as an end point in clinical trials would be enhanced if it could be demonstrated that progression was closely linked to future coronary events. If, on the other hand, asymptomatic progression were only a meaningless angiographic phenomenon that had no relation to outcome, its value as an end point would be severely restricted.
In a recent controlled clinical trial in our center,3,4 335 of the 383 patients who were enrolled underwent repeat coronary arteriography after 2 years, with coronary lesions measured quantitatively. The intervention tested, nicardipine, had no effect on the evolution of established coronary stenoses, but in a retrospective analysis, it significantly reduced progression of minimal lesions.4 Among the 335 patients with two arteriograms, 141 (42%) had progression of at least one coronary lesion defined as an increase in diameter stenosis by .15%. The purpose of this study is to compare the subsequent outcome of progressors with nonprogressors and to compare coronary progression with other more established prognostic indicators in coronary disease.
See p 1399 Methods 
Patient Selection
The design features of the trial, including criteria for patient selection, have been described in detail. 3, 4 Young patients with mild, diffuse coronary disease were selected because a previous study from our institution demonstrated that such patients were most likely to develop progression.5 The specific inclusion criteria were based on an extent score defined as the number of coronary segments containing stenoses of 5-75%, with the coronary tree divided into the 15 segments defined in the Coronary Artery Surgery Study protocol.6 Patients were eligible if they were aged 50 years or less with an extent score of at least 4, 51-60 years with a score of at least 5, or 61-65 years with a score of 6 or more.
Exclusion criteria were 1) previous coronary bypass surgery or coronary angioplasty, 2) planned coronary The Cardiovascular Angiographic Analysis System (CAAS) developed by Reiber et al7,8 was used to measure lesions quantitatively in this study, as previously described in detail.4'9 An experienced technician blinded to the order of films and patient identity used CAAS to measure the coronary stenosis from the frame selected by the radiologist. The computer-estimated interpolated diameter was calculated and used as the "normal" diameter of the arterial segment when possible; occasionally, a user-defined reference segment was used. Two orthogonal views were not measured and averaged because we have found previously that measurements of the view showing the stenosis at its most severe were sufficient.10 Likewise, as demonstrated by Reiber et al,11 it is not necessary to measure and average adjacent frames. Stenoses <25% on both films were interpreted visually but not by quantitative arteriography when the radiologist judged that no change had occurred. Lesions in arteries less than 1 mm in diameter were also read visually because CAAS is less reliable under these circumstances. All except 5% (11 of 218) of the lesions with progression in this study were measured quantitatively.
We have investigated the reproducibility of repeated measurements using CAAS under conditions similar to this study.9 For diameter stenosis and minimum diameter, the standard deviations for repeat measurements are respectively 6.7% and 0.197 mm from pairs of angiograms filmed at an interval of 1-6 months. A change of <2 SD (.15% for diameter stenosis or >0.4 mm for minimum diameter) in any vessel measured at the baseline angiogram is therefore likely to represent true change. These criteria were thus used to define progression in this study. The diameter stenosis definition of progression was met by 141 patients, all except 15 of whom also met the minimum diameter criterion. Conversely, the minimum diameter definition was met by 140 patients, all except 14 of whom also met the diameter stenosis definition. The results of this study are presented using only the diameter stenosis definition for simplicity, because the results with either criterion are almost identical.
Follow-up
After patients completed the study, they were returned to the care of their own cardiologist who, in most cases, followed them in our outpatient clinic. None of the patients took nicardipine because the drug had not yet been approved for clinical use. Five of the 335 patients who underwent repeat coronary arteriography were subsequently lost to follow-up. Two of these cedures and the other three after 9, 21, and 25 months. Myocardial infarction was diagnosed during follow-up according to the same criteria that were used during the original trial.3 Two of the 21 deaths during follow-up were due to lung cancer and were classified as noncardiac. The causes of the other 19 deaths were presumed to be cardiac: Nine were out-of-hospital and sudden, six were in-hospital and due to acute complications of myocardial infarction, and four were soon after revascularization, in three cases as a consequence of periprocedural infarction.
The decision to perform coronary bypass surgery or coronary angioplasty was made by the patient's own cardiologist and was not influenced by the patient's participation in the study. Revascularization was almost never recommended based on the results of the repeat arteriogram because most patients had few symptoms at that point. The average interval between arteriography and revascularization was 35+±-17 months, only slightly shorter than the average interval between arteriography and cardiac death or myocardial infarction, 40±13 months, indicating that revascularization procedures represent new coronary events and not merely a consequence of the coronary arteriographic findings.
Statistical Methods
The factors included in analyses were age, sex, hypertension, diabetes, smoking, family history, angina, myQcardial infarction, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein (HDL) Figure 1 depicts the product-limit estimates of time to different end points for progressors and nonprogressors. For cardiac death, cardiac death or myocardial infarction, and any coronary event, the curves are widely divergent and the difference highly significant (p<0.001). For revascularization, the difference between the curves is statistically significant (p=0.014) but not as large as for the other end points.
Treatment and Subsequent Coronary Events
Among the 168 patients originally randomized to nicardipine who completed the study, 59 developed a cardiac event during follow-up after cessation of the study drug and repeat arteriography compared with 53 of 167 in the placebo group (relative risk, 1.1; p=0.5 1). However, cardiac death occurred in 13 nicardipine and six placebo patients (relative risk, 2.2; p=0.10), and cardiac death or myocardial infarction occurred in 25 nicardipine and 15 placebo patients (relative risk, 1.7; p=0.10). The median time from the end of the trial to cardiac death or myocardial infarction was 14 months in the nicardipine group and 15 months in the placebo group.
As previously reported,4 nonfatal myocardial infarction occurred during the trial in 14 nicardipine and eight placebo patients; two nicardipine and three placebo patients died from coronary disease. Cardiac mortality during the trial and follow-up totaled 15 of the original 192 patients randomized to nicardipine and nine of the 191 allocated to the placebo group (relative risk, 1.7; p=0.21). Cardiac mortality or myocardial infarction occurred in 35 nicardipine and 24 placebo patients (relative risk, 1.5; p=0.13).
When 21 clinical and angiographic variables were stratified according to treatment allocation, no significant treatment interactions were seen for the end points of cardiac death, revascularization, or any cardiac event during follow-up (alwaysp>0.05). When the same analysis was done for the combined end point of cardiac death or myocardial infarction, a significant interaction (p<O.OOl) was seen between the number of diseased vessels and treatment allocation, as shown in Table 2 . Previous nicardipine treatment was associated with more of these events in patients with coronary stenoses c50% or one-vessel disease at the second angiogram and less in those with three-vessel disease, even though no patient took the drug after the end of the study.
Progression at the second arteriogram predicted subsequent cardiac death both in patients who had been allocated to placebo and in patients who had been allocated to nicardipine. The relative risk was 6.7 (p=0.05) in the former group and 8.3 (p<0.01) in the latter. Progression was also a predictor for the combined end point of cardiac death or myocardial infarction in both groups. The relative risk was 2.5 (p=0.07) in placebo patients and 2.3 (p=0.03) in nicardipine patients. Finally, progression predicted any coronary event during follow-up, with a relative risk of 1.6 (p=0.03) in the placebo group and 2.5 (p=0.01) in the nicardipine group. The difference between the treatment groups for each of these end approach statistical significance.
points did not Multivariable Analyses of Predictors of Coronary Events
To assess the relative contribution of progression as a predictor of coronary events compared with more traditional variables, a stepwise multivariable Cox regression model of time to event was used. The results of these analyses are listed in Table 3 . For cardiac death, three variables were retained as predictors: low ejection fraction (p=0.001), progression (p=0.001), and hypertension (p=0.011). For the combined end point of cardiac death or myocardial infarction, low ejection fraction (p=0.001) and progression (p=0.004) were predictive. A history of angina (p=0.001), high triglycerides (p=0.016), and number of diseased vessels (p=0.005) were predictors of revascularization by multivariable analysis. The significant predictors by multivariable analysis for any coronary event were progression (p=0.034), angina (p=0.037), low ejection fraction (p=0.042), low HDL cholesterol (p=0.049), and number of diseased vessels (p=0.032).
The number of diseased vessels (coronary arteries with stenoses >50%) was a strong predictor of revascularization (p<0.001 in univariable analyses, p=0.005 in multivariable analyses) and was therefore also an important predictor of any cardiac event (p<0.001 in univariable analyses, p=0.032 in multivariable analyses). However, it was not found to be an important predictor of cardiac death (p=0.015 in univariable analyses but not significant in multivariable analyses) or cardiac death or nonfatal infarction (not significant in either univariable or multivariable analyses) except in relation to treatment group, as discussed in the preceding section. Not surprisingly, the distribution of diseased vessels was strongly related (p<0.001) to progression: 94% of progressors had one or more diseased vessels and 65% had two or more diseased vessels compared with 74% and 38%, respectively, for nonprogressors. Discussion The results of this study indicate that patients whose coronary disease has recently progressed are at higher risk for future coronary events than are patients whose lesions have not changed. The relative risk was particularly high for cardiac death, 7.3, but for the combined end point of any cardiac event was still 1.7. In the Cox 
Pathophysiological Considerations
The angiographic patterns and variations of coronary disease progression have not been clearly defined. Bruschke et al,27 from a study of 168 medically treated patients who had three arteriograms for clinical reasons, concluded that progression is highly unpredictable and that progression in the past is of little value in predicting future progression. In smaller series from our institution, patients who progressed between their first and second angiograms had a somewhat higher than predicted progression rate between their second and third angiograms.28 These studies have several major limitations: The small number of patients who undergo more than two or three coronary arteriograms are unrepresentative, and the visual assessment of progression from films done for clinical purposes is inaccurate.
The results of this study imply that patients who have recently progressed are more likely to do so again; their higher incidence of future coronary events undoubtedly reflects a higher incidence of underlying progression. Whether this future progression occurs most often at the sites that have recently progressed or elsewhere is an important question that cannot be answered by our results. If progression occurs elsewhere, it implies that patient-related factors are more likely to be causative. If progression tends to recur on a stenosis that has recently progressed, lesion-specific factors are more likely to predominate, and treatment directed at the stenosis might have a greater chance of success.
Limitations of the Study
The inclusion and exclusion criteria for the clinical trial from which the study population was derived probably influenced our results. For example, age was not a predictor of coronary events, possibly because patients older than 70 years were excluded. Few patients had low ejection fractions because a value of 240% was required for enrollment into the original trial. Despite this, ejection fraction still emerged as a strong predictive variable. All patients had at least four coronary lesions and were therefore at high risk for progression; 42% of patients progressed during the 2-year interval between arteriograms, and the perpatient risk of progression undoubtedly remained high during follow-up. These conditions favor the emergence of progression as a strong predictor of clinical events. In a population with more indolent coronary disease, other risk factors for coronary events could predominate.
In contrast to previous studies,S5,23,25-" where progression was determined by visual assessment, this study used quantitative measurements. Patients were enrolled and followed prospectively; coronary arteriography was repeated after a predetermined interval, and very few patients dropped out. The results are therefore less likely to be biased than are retrospective studies of patients recatheterized for symptoms.
Four of the cardiac deaths in this study were related to coronary revascularization procedures, in three cases as a consequence of periprocedural infarction. Revascularization was being done in each of these four patients for unstable angina. If these patients are not classified as cardiac deaths, the results of the study do not change substantially: Thirteen of the 15 cardiac deaths, instead of 16 of 19, would then have occurred in patients who progressed during the study, and the relative risk of progression would be 9.1 instead of 7.3 for cardiac death.
Nicardipine and Coronary Events
The finding that cardiac death or myocardial infarction occurred more frequently after the end of the study in patients who had been allocated to nicardipine compared with placebo was unexpected because these events occurred, on the average, more than 1 year after all study drugs were discontinued and because during the trial, nicardipine had no detectable influence on the evolution of established coronary atherosclerosis.4 Al 
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